Prospective Observational Analysis of Circulating Endocan Levels in Patients Presenting With Acute Diverticulitis

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorIRCCS Ospedale San Raffaele

About this trial

Quantify the level of endocan in blood samples collected from patients with acute diverticulitis in the emergency department. Determine if endocan levels are correlated with the severity of diverticulitis according to the WSES classification. Assess whether patients requiring emergency surgical intervention have higher endocan values compared to others.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients who have signed informed consent

Patients who are affected by acute diverticulitis after clinical evaluation and imaging (i.e. u.s. or CeCT)

Disqualifiers

Immunosuppressed patients

Patients suffering chronic inflammatory diseases

Patients with concomitant malignancy, cardiac, renal and haepatic failure

History of major vascular surgery (aneurysmectomy)

Trial population

Patients affected by acute diverticulitis in the emergency department

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

60 Participants
are grouped into 1 trial group
Group A: patients with acute diverticulitis

Trial outcomes

Primary outcomes

1

Endocan serum level at admission

To evaluate the correlation between blood concentration of endocan and severity of diverticulitis

Time frame
The serum of the patients enrolled inthe study will be collected within two hours from emergency room registation and tested for ENDOCAN

Secondary outcomes

1

Predictive value of endocan in determining which patients need emergency surgery

Concentration of endocan in grade 3-4 WSES compared to grade1-2

Time frame
Patients will undergo diverticulitis evaluations (per WSES criteria) within 3 hours of Emergency room admission and study enrollment
2

Prognostic value of endocan in determining the risk of recurrent diveritculitis

Concentration of endocan in patient who develop a recurrence after 1 year follow-up

Time frame
From discharge after definitive tretament till 12 months follow-up

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: